title: Is hospitalization after TIA cost-effective on the basis of treatment with tPA?
abstract: A 24-hour hospitalization for TIA could be cost-effective simply by increasing the likelihood that patients will receive tissue plasminogen activator if a stroke occurs. The authors performed a cost-utility analysis of 24-hour hospitalization for patients diagnosed with recent TIA. The overall cost-effectiveness ratio was 55,044 dollars per quality-adjusted life-year, a value considered borderline cost-effective. For patients with higher risk of stroke, admission was cost-effective.
authors.affiliation: Department of Neurology, University of California, San Francisco, CA 94143-0114, USA.
authors.forename: Mai N
authors.initials: MN
authors.lastname: Nguyen-Huynh
authors.forename: S Claiborne
authors.initials: SC
authors.lastname: Johnston
mesh_terms: D000046:Academic Medical Centers / Q000191:economics / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004636:Emergency Service, Hospital / Q000191:economics / Q000706:statistics & numerical data; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000191:economics*; D008390:Markov Chains; D015233:Models, Statistical; D019057:Quality-Adjusted Life Years; D012042:Registries; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D015912:Thrombolytic Therapy / Q000191:economics* / Q000592:standards; D010959:Tissue Plasminogen Activator / Q000191:economics / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator